
    
      The first phase of the clinical trial is an open trial. The study will enroll 14 men and
      women aged 18 to 30 years, inclusive, who meet the inclusion criteria and have no exclusion
      criteria, whose data will be used for subsequent analysis of safety and immunogenicity.

      The second phase of the clinical trial is a simple, blind, placebo-controlled, randomized,
      parallel-group study. The study will enroll 86 men and women aged 18 to 60 years, inclusive,
      who meet the inclusion criteria and have no exclusion criteria whose, the data will be used
      for subsequent analysis of safety and immunogenicity.

      If volunteers drop out of the study, they will not be replaced.
    
  